Unveiling a New Horizon in Prostate Cancer Treatment: Predicting Chemo Resistance
A groundbreaking study has unveiled a novel method to predict resistance to cabazitaxel, a chemotherapy drug commonly used in treating advanced prostate cancer. This research, conducted with samples from over 200 men, highlights a significant association between chromosomal instability in circulating tumour cells (CTCs) and poorer treatment outcomes with cabazitaxel.
The study demonstrates the feasibility of assessing chromosomal instability in CTCs, a simple yet powerful marker that can predict clinical outcomes, including survival and tumour response. This breakthrough could revolutionize treatment decisions for advanced prostate cancer patients, potentially sparing them the unnecessary toxicity of ineffective chemotherapy and guiding them towards more effective alternatives.
The Complexity of Treatment Decisions for mCRPC
For men with metastatic castration-resistant prostate cancer (mCRPC), treatment decisions become increasingly complex as the disease progresses. These patients have often already undergone hormone-targeting therapies and chemotherapy, leaving oncologists with a challenging question: what's next?
Cabazitaxel, a chemotherapy drug, has been proven to extend survival more than switching to another hormone-targeting agent. The CARD trial, a landmark study involving participants from over 60 sites across 13 European countries, confirmed cabazitaxel's superiority over a second androgen receptor pathway inhibitor (ARPI) in this setting, establishing it as the standard of care for patients progressing on docetaxel and ARPIs.
However, the harsh side effects of chemotherapy, such as fatigue, infections, and neuropathy, can be endured without additional survival benefits. Until now, there has been no reliable way to predict who will benefit and who will not.
Analyzing Blood Samples for CTCs
The research team analyzed blood samples from CARD trial participants who had received docetaxel and progressed within 12 months of starting ARPI treatment. CTCs are rare in whole blood, so the researchers employed an innovative technique to isolate these cells without traditional enrichment methods like immunomagnetic capture.
They treated four blood slides to remove red blood cells, stained them with fluorescent antibodies, and used semi-automated analysis to count CTCs among white blood cells. A proprietary algorithm then categorized cells as chromosomally unstable or 'normal' based solely on cell morphology.
The Significance of Chromosomal Instability
Advanced prostate cancer patients with high chromosomal instability in their CTCs experienced significantly worse outcomes. Median overall survival dropped from about 15 months in the low-instability group to just under nine months in the high-instability group. The most clinically relevant insight was predictive: when chromosomal instability was high, cabazitaxel did not outperform switching to another hormone-targeting drug. This suggests that chromosomal instability in CTCs could serve as a biomarker to guide treatment decisions, helping doctors avoid ineffective chemotherapy and consider alternative strategies for certain patients.
Towards Precision Oncology for Advanced Prostate Cancer
Ossian Longoria, the study's lead Clinical Research Fellow at the ICR, emphasized the importance of clinical trial outcomes in guiding decision-making for most patients. However, predicting an individual's response to treatment remains the holy grail in oncology. Molecular markers are increasingly offering a deeper understanding of what drives each patient's cancer.
Professor Johann de Bono, a senior researcher and Regius Professor of Cancer Research at the ICR, explained that these findings build on decades of research, representing a significant breakthrough in the liquid biopsy and circulating tumour cell fields. This study is the first prospective confirmation that chromosomal instability predicts cabazitaxel resistance in patients with advanced prostate cancer.
